nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP2A6—lung cancer	0.152	0.441	CbGaD
Buprenorphine—ABCG2—lung cancer	0.136	0.395	CbGaD
Buprenorphine—ABCB1—lung cancer	0.0567	0.164	CbGaD
Buprenorphine—UGT1A9—Irinotecan—lung cancer	0.0243	0.055	CbGbCtD
Buprenorphine—ABCG2—Topotecan—lung cancer	0.0224	0.0507	CbGbCtD
Buprenorphine—ABCG2—Gefitinib—lung cancer	0.0205	0.0464	CbGbCtD
Buprenorphine—ABCG2—Teniposide—lung cancer	0.0199	0.045	CbGbCtD
Buprenorphine—ABCG2—Erlotinib—lung cancer	0.0121	0.0274	CbGbCtD
Buprenorphine—CYP3A5—Gefitinib—lung cancer	0.0114	0.0257	CbGbCtD
Buprenorphine—ABCG2—Paclitaxel—lung cancer	0.0111	0.0251	CbGbCtD
Buprenorphine—CYP3A5—Teniposide—lung cancer	0.011	0.0249	CbGbCtD
Buprenorphine—ABCG2—Irinotecan—lung cancer	0.011	0.0248	CbGbCtD
Buprenorphine—CYP2C19—Gefitinib—lung cancer	0.00917	0.0207	CbGbCtD
Buprenorphine—ABCG2—Cisplatin—lung cancer	0.00893	0.0202	CbGbCtD
Buprenorphine—CYP2C19—Teniposide—lung cancer	0.00889	0.0201	CbGbCtD
Buprenorphine—ABCG2—Etoposide—lung cancer	0.00877	0.0198	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Paclitaxel—lung cancer	0.0082	0.0185	CbGbCtD
Buprenorphine—CYP3A7—Paclitaxel—lung cancer	0.0082	0.0185	CbGbCtD
Buprenorphine—CYP3A7—Irinotecan—lung cancer	0.00809	0.0183	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Irinotecan—lung cancer	0.00809	0.0183	CbGbCtD
Buprenorphine—ABCB1—Topotecan—lung cancer	0.00809	0.0183	CbGbCtD
Buprenorphine—ABCG2—Docetaxel—lung cancer	0.00803	0.0181	CbGbCtD
Buprenorphine—CYP2C9—Gefitinib—lung cancer	0.00762	0.0172	CbGbCtD
Buprenorphine—ABCB1—Gefitinib—lung cancer	0.0074	0.0167	CbGbCtD
Buprenorphine—CYP2C9—Teniposide—lung cancer	0.00739	0.0167	CbGbCtD
Buprenorphine—CYP2D6—Gefitinib—lung cancer	0.00697	0.0158	CbGbCtD
Buprenorphine—CYP3A5—Crizotinib—lung cancer	0.00697	0.0157	CbGbCtD
Buprenorphine—CYP3A5—Erlotinib—lung cancer	0.00672	0.0152	CbGbCtD
Buprenorphine—CYP2C8—Erlotinib—lung cancer	0.00646	0.0146	CbGbCtD
Buprenorphine—CYP3A5—Paclitaxel—lung cancer	0.00615	0.0139	CbGbCtD
Buprenorphine—CYP3A5—Irinotecan—lung cancer	0.00607	0.0137	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—lung cancer	0.00598	0.0135	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Docetaxel—lung cancer	0.00593	0.0134	CbGbCtD
Buprenorphine—CYP3A7—Docetaxel—lung cancer	0.00593	0.0134	CbGbCtD
Buprenorphine—CYP2C8—Paclitaxel—lung cancer	0.00591	0.0134	CbGbCtD
Buprenorphine—ABCG2—Methotrexate—lung cancer	0.0058	0.0131	CbGbCtD
Buprenorphine—ABCB1—Vinorelbine—lung cancer	0.0057	0.0129	CbGbCtD
Buprenorphine—CYP2D6—Vinorelbine—lung cancer	0.00537	0.0121	CbGbCtD
Buprenorphine—CYP1A2—Erlotinib—lung cancer	0.005	0.0113	CbGbCtD
Buprenorphine—CYP3A5—Etoposide—lung cancer	0.00486	0.011	CbGbCtD
Buprenorphine—CYP3A4—Topotecan—lung cancer	0.00485	0.011	CbGbCtD
Buprenorphine—CYP2C8—Etoposide—lung cancer	0.00467	0.0106	CbGbCtD
Buprenorphine—ABCB1—Crizotinib—lung cancer	0.00453	0.0102	CbGbCtD
Buprenorphine—CYP3A5—Docetaxel—lung cancer	0.00445	0.0101	CbGbCtD
Buprenorphine—CYP3A4—Gefitinib—lung cancer	0.00443	0.01	CbGbCtD
Buprenorphine—ABCB1—Gemcitabine—lung cancer	0.00443	0.01	CbGbCtD
Buprenorphine—ABCB1—Erlotinib—lung cancer	0.00437	0.00988	CbGbCtD
Buprenorphine—CYP3A4—Teniposide—lung cancer	0.0043	0.00971	CbGbCtD
Buprenorphine—CYP2C9—Paclitaxel—lung cancer	0.00412	0.00932	CbGbCtD
Buprenorphine—CYP2D6—Erlotinib—lung cancer	0.00412	0.00931	CbGbCtD
Buprenorphine—ABCB1—Paclitaxel—lung cancer	0.004	0.00905	CbGbCtD
Buprenorphine—ABCB1—Irinotecan—lung cancer	0.00395	0.00893	CbGbCtD
Buprenorphine—CYP1A2—Etoposide—lung cancer	0.00362	0.00818	CbGbCtD
Buprenorphine—ABCB1—Vinblastine—lung cancer	0.00351	0.00794	CbGbCtD
Buprenorphine—CYP3A4—Vinorelbine—lung cancer	0.00341	0.00772	CbGbCtD
Buprenorphine—CYP2C9—Cisplatin—lung cancer	0.00332	0.0075	CbGbCtD
Buprenorphine—CYP2D6—Vinblastine—lung cancer	0.00331	0.00748	CbGbCtD
Buprenorphine—ABCB1—Cisplatin—lung cancer	0.00322	0.00728	CbGbCtD
Buprenorphine—ABCB1—Etoposide—lung cancer	0.00316	0.00715	CbGbCtD
Buprenorphine—ABCB1—Docetaxel—lung cancer	0.00289	0.00654	CbGbCtD
Buprenorphine—CYP3A4—Crizotinib—lung cancer	0.00272	0.00614	CbGbCtD
Buprenorphine—CYP3A4—Erlotinib—lung cancer	0.00262	0.00592	CbGbCtD
Buprenorphine—CYP3A4—Paclitaxel—lung cancer	0.0024	0.00542	CbGbCtD
Buprenorphine—CYP3A4—Irinotecan—lung cancer	0.00237	0.00535	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—lung cancer	0.00216	0.00488	CbGbCtD
Buprenorphine—CYP3A4—Vinblastine—lung cancer	0.0021	0.00476	CbGbCtD
Buprenorphine—ABCB1—Methotrexate—lung cancer	0.00209	0.00472	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—lung cancer	0.00203	0.00459	CbGbCtD
Buprenorphine—CYP3A4—Etoposide—lung cancer	0.0019	0.00428	CbGbCtD
Buprenorphine—CYP3A4—Docetaxel—lung cancer	0.00173	0.00392	CbGbCtD
Buprenorphine—CYP3A4—Doxorubicin—lung cancer	0.00129	0.00292	CbGbCtD
Buprenorphine—Naltrexone—UGT1A1—lung cancer	0.000868	0.631	CrCbGaD
Buprenorphine—Naltrexone—ABCB1—lung cancer	0.000203	0.148	CrCbGaD
Buprenorphine—Naloxone—ALB—lung cancer	0.000155	0.113	CrCbGaD
Buprenorphine—Naloxone—ABCB1—lung cancer	0.000148	0.108	CrCbGaD
Buprenorphine—Dyspepsia—Paclitaxel—lung cancer	4.85e-05	0.000384	CcSEcCtD
Buprenorphine—Body temperature increased—Cisplatin—lung cancer	4.85e-05	0.000384	CcSEcCtD
Buprenorphine—Asthenia—Irinotecan—lung cancer	4.85e-05	0.000384	CcSEcCtD
Buprenorphine—Fatigue—Etoposide—lung cancer	4.84e-05	0.000384	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	4.84e-05	0.000383	CcSEcCtD
Buprenorphine—Pain—Etoposide—lung cancer	4.81e-05	0.000381	CcSEcCtD
Buprenorphine—Constipation—Etoposide—lung cancer	4.81e-05	0.000381	CcSEcCtD
Buprenorphine—Decreased appetite—Paclitaxel—lung cancer	4.79e-05	0.000379	CcSEcCtD
Buprenorphine—Dry mouth—Docetaxel—lung cancer	4.76e-05	0.000377	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Doxorubicin—lung cancer	4.76e-05	0.000377	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Paclitaxel—lung cancer	4.76e-05	0.000377	CcSEcCtD
Buprenorphine—Fatigue—Paclitaxel—lung cancer	4.75e-05	0.000376	CcSEcCtD
Buprenorphine—Asthenia—Gemcitabine—lung cancer	4.72e-05	0.000374	CcSEcCtD
Buprenorphine—Pain—Paclitaxel—lung cancer	4.71e-05	0.000373	CcSEcCtD
Buprenorphine—Constipation—Paclitaxel—lung cancer	4.71e-05	0.000373	CcSEcCtD
Buprenorphine—Confusional state—Docetaxel—lung cancer	4.71e-05	0.000373	CcSEcCtD
Buprenorphine—Pharyngitis—Methotrexate—lung cancer	4.7e-05	0.000372	CcSEcCtD
Buprenorphine—Urinary tract disorder—Methotrexate—lung cancer	4.68e-05	0.000371	CcSEcCtD
Buprenorphine—Anaphylactic shock—Docetaxel—lung cancer	4.67e-05	0.00037	CcSEcCtD
Buprenorphine—Oedema—Docetaxel—lung cancer	4.67e-05	0.00037	CcSEcCtD
Buprenorphine—Pruritus—Gemcitabine—lung cancer	4.66e-05	0.000369	CcSEcCtD
Buprenorphine—Urethral disorder—Methotrexate—lung cancer	4.64e-05	0.000368	CcSEcCtD
Buprenorphine—Infection—Docetaxel—lung cancer	4.64e-05	0.000367	CcSEcCtD
Buprenorphine—Weight decreased—Doxorubicin—lung cancer	4.64e-05	0.000367	CcSEcCtD
Buprenorphine—Feeling abnormal—Etoposide—lung cancer	4.63e-05	0.000367	CcSEcCtD
Buprenorphine—Diarrhoea—Irinotecan—lung cancer	4.62e-05	0.000366	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Etoposide—lung cancer	4.6e-05	0.000364	CcSEcCtD
Buprenorphine—Shock—Docetaxel—lung cancer	4.59e-05	0.000364	CcSEcCtD
Buprenorphine—Nervous system disorder—Docetaxel—lung cancer	4.58e-05	0.000363	CcSEcCtD
Buprenorphine—Infestation NOS—Doxorubicin—lung cancer	4.57e-05	0.000362	CcSEcCtD
Buprenorphine—Infestation—Doxorubicin—lung cancer	4.57e-05	0.000362	CcSEcCtD
Buprenorphine—Visual impairment—Methotrexate—lung cancer	4.57e-05	0.000362	CcSEcCtD
Buprenorphine—Tachycardia—Docetaxel—lung cancer	4.56e-05	0.000361	CcSEcCtD
Buprenorphine—Feeling abnormal—Paclitaxel—lung cancer	4.54e-05	0.00036	CcSEcCtD
Buprenorphine—Skin disorder—Docetaxel—lung cancer	4.54e-05	0.000359	CcSEcCtD
Buprenorphine—Hypersensitivity—Cisplatin—lung cancer	4.52e-05	0.000358	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Paclitaxel—lung cancer	4.51e-05	0.000357	CcSEcCtD
Buprenorphine—Diarrhoea—Gemcitabine—lung cancer	4.5e-05	0.000357	CcSEcCtD
Buprenorphine—Dizziness—Irinotecan—lung cancer	4.47e-05	0.000354	CcSEcCtD
Buprenorphine—Urticaria—Etoposide—lung cancer	4.46e-05	0.000354	CcSEcCtD
Buprenorphine—Anorexia—Docetaxel—lung cancer	4.45e-05	0.000353	CcSEcCtD
Buprenorphine—Abdominal pain—Etoposide—lung cancer	4.44e-05	0.000352	CcSEcCtD
Buprenorphine—Body temperature increased—Etoposide—lung cancer	4.44e-05	0.000352	CcSEcCtD
Buprenorphine—Conjunctivitis—Doxorubicin—lung cancer	4.44e-05	0.000352	CcSEcCtD
Buprenorphine—Urinary tract infection—Doxorubicin—lung cancer	4.44e-05	0.000352	CcSEcCtD
Buprenorphine—Eye disorder—Methotrexate—lung cancer	4.43e-05	0.000351	CcSEcCtD
Buprenorphine—Tinnitus—Methotrexate—lung cancer	4.42e-05	0.00035	CcSEcCtD
Buprenorphine—Asthenia—Cisplatin—lung cancer	4.4e-05	0.000349	CcSEcCtD
Buprenorphine—Cardiac disorder—Methotrexate—lung cancer	4.4e-05	0.000348	CcSEcCtD
Buprenorphine—Sweating—Doxorubicin—lung cancer	4.38e-05	0.000347	CcSEcCtD
Buprenorphine—Urticaria—Paclitaxel—lung cancer	4.38e-05	0.000347	CcSEcCtD
Buprenorphine—Hypotension—Docetaxel—lung cancer	4.36e-05	0.000346	CcSEcCtD
Buprenorphine—Abdominal pain—Paclitaxel—lung cancer	4.36e-05	0.000345	CcSEcCtD
Buprenorphine—Body temperature increased—Paclitaxel—lung cancer	4.36e-05	0.000345	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Doxorubicin—lung cancer	4.32e-05	0.000342	CcSEcCtD
Buprenorphine—Angiopathy—Methotrexate—lung cancer	4.3e-05	0.00034	CcSEcCtD
Buprenorphine—Vomiting—Irinotecan—lung cancer	4.3e-05	0.00034	CcSEcCtD
Buprenorphine—Sinusitis—Doxorubicin—lung cancer	4.29e-05	0.00034	CcSEcCtD
Buprenorphine—Immune system disorder—Methotrexate—lung cancer	4.28e-05	0.000339	CcSEcCtD
Buprenorphine—Mediastinal disorder—Methotrexate—lung cancer	4.27e-05	0.000338	CcSEcCtD
Buprenorphine—Rash—Irinotecan—lung cancer	4.26e-05	0.000337	CcSEcCtD
Buprenorphine—Dermatitis—Irinotecan—lung cancer	4.26e-05	0.000337	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Docetaxel—lung cancer	4.25e-05	0.000337	CcSEcCtD
Buprenorphine—Chills—Methotrexate—lung cancer	4.25e-05	0.000337	CcSEcCtD
Buprenorphine—Headache—Irinotecan—lung cancer	4.23e-05	0.000335	CcSEcCtD
Buprenorphine—Insomnia—Docetaxel—lung cancer	4.22e-05	0.000335	CcSEcCtD
Buprenorphine—Diarrhoea—Cisplatin—lung cancer	4.2e-05	0.000332	CcSEcCtD
Buprenorphine—Paraesthesia—Docetaxel—lung cancer	4.19e-05	0.000332	CcSEcCtD
Buprenorphine—Vomiting—Gemcitabine—lung cancer	4.18e-05	0.000331	CcSEcCtD
Buprenorphine—Bradycardia—Doxorubicin—lung cancer	4.18e-05	0.000331	CcSEcCtD
Buprenorphine—Dyspnoea—Docetaxel—lung cancer	4.16e-05	0.00033	CcSEcCtD
Buprenorphine—Somnolence—Docetaxel—lung cancer	4.15e-05	0.000329	CcSEcCtD
Buprenorphine—Mental disorder—Methotrexate—lung cancer	4.15e-05	0.000329	CcSEcCtD
Buprenorphine—Rash—Gemcitabine—lung cancer	4.15e-05	0.000329	CcSEcCtD
Buprenorphine—Dermatitis—Gemcitabine—lung cancer	4.15e-05	0.000328	CcSEcCtD
Buprenorphine—Hypersensitivity—Etoposide—lung cancer	4.14e-05	0.000328	CcSEcCtD
Buprenorphine—Erythema—Methotrexate—lung cancer	4.12e-05	0.000327	CcSEcCtD
Buprenorphine—Malnutrition—Methotrexate—lung cancer	4.12e-05	0.000327	CcSEcCtD
Buprenorphine—Headache—Gemcitabine—lung cancer	4.12e-05	0.000327	CcSEcCtD
Buprenorphine—Rhinitis—Doxorubicin—lung cancer	4.11e-05	0.000326	CcSEcCtD
Buprenorphine—Dyspepsia—Docetaxel—lung cancer	4.11e-05	0.000326	CcSEcCtD
Buprenorphine—Hypoaesthesia—Doxorubicin—lung cancer	4.08e-05	0.000323	CcSEcCtD
Buprenorphine—Pharyngitis—Doxorubicin—lung cancer	4.07e-05	0.000322	CcSEcCtD
Buprenorphine—Decreased appetite—Docetaxel—lung cancer	4.06e-05	0.000322	CcSEcCtD
Buprenorphine—Hypersensitivity—Paclitaxel—lung cancer	4.06e-05	0.000322	CcSEcCtD
Buprenorphine—Urinary tract disorder—Doxorubicin—lung cancer	4.05e-05	0.000321	CcSEcCtD
Buprenorphine—Oedema peripheral—Doxorubicin—lung cancer	4.04e-05	0.00032	CcSEcCtD
Buprenorphine—Dysgeusia—Methotrexate—lung cancer	4.04e-05	0.00032	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Docetaxel—lung cancer	4.03e-05	0.000319	CcSEcCtD
Buprenorphine—Asthenia—Etoposide—lung cancer	4.03e-05	0.000319	CcSEcCtD
Buprenorphine—Connective tissue disorder—Doxorubicin—lung cancer	4.03e-05	0.000319	CcSEcCtD
Buprenorphine—Fatigue—Docetaxel—lung cancer	4.03e-05	0.000319	CcSEcCtD
Buprenorphine—Urethral disorder—Doxorubicin—lung cancer	4.02e-05	0.000319	CcSEcCtD
Buprenorphine—Nausea—Irinotecan—lung cancer	4.01e-05	0.000318	CcSEcCtD
Buprenorphine—Constipation—Docetaxel—lung cancer	3.99e-05	0.000316	CcSEcCtD
Buprenorphine—Pain—Docetaxel—lung cancer	3.99e-05	0.000316	CcSEcCtD
Buprenorphine—Back pain—Methotrexate—lung cancer	3.99e-05	0.000316	CcSEcCtD
Buprenorphine—Pruritus—Etoposide—lung cancer	3.98e-05	0.000315	CcSEcCtD
Buprenorphine—Visual impairment—Doxorubicin—lung cancer	3.95e-05	0.000313	CcSEcCtD
Buprenorphine—Asthenia—Paclitaxel—lung cancer	3.95e-05	0.000313	CcSEcCtD
Buprenorphine—Nausea—Gemcitabine—lung cancer	3.91e-05	0.00031	CcSEcCtD
Buprenorphine—Vomiting—Cisplatin—lung cancer	3.9e-05	0.000309	CcSEcCtD
Buprenorphine—Pruritus—Paclitaxel—lung cancer	3.9e-05	0.000309	CcSEcCtD
Buprenorphine—Vision blurred—Methotrexate—lung cancer	3.89e-05	0.000308	CcSEcCtD
Buprenorphine—Rash—Cisplatin—lung cancer	3.87e-05	0.000306	CcSEcCtD
Buprenorphine—Dermatitis—Cisplatin—lung cancer	3.86e-05	0.000306	CcSEcCtD
Buprenorphine—Feeling abnormal—Docetaxel—lung cancer	3.85e-05	0.000305	CcSEcCtD
Buprenorphine—Diarrhoea—Etoposide—lung cancer	3.84e-05	0.000305	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—lung cancer	3.83e-05	0.000304	CcSEcCtD
Buprenorphine—Ill-defined disorder—Methotrexate—lung cancer	3.83e-05	0.000303	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—lung cancer	3.82e-05	0.000303	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Docetaxel—lung cancer	3.82e-05	0.000302	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—lung cancer	3.81e-05	0.000302	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—lung cancer	3.81e-05	0.000302	CcSEcCtD
Buprenorphine—Diarrhoea—Paclitaxel—lung cancer	3.77e-05	0.000299	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—lung cancer	3.72e-05	0.000295	CcSEcCtD
Buprenorphine—Malaise—Methotrexate—lung cancer	3.72e-05	0.000295	CcSEcCtD
Buprenorphine—Dizziness—Etoposide—lung cancer	3.72e-05	0.000294	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—lung cancer	3.71e-05	0.000293	CcSEcCtD
Buprenorphine—Vertigo—Methotrexate—lung cancer	3.71e-05	0.000293	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—lung cancer	3.7e-05	0.000293	CcSEcCtD
Buprenorphine—Abdominal pain—Docetaxel—lung cancer	3.69e-05	0.000292	CcSEcCtD
Buprenorphine—Body temperature increased—Docetaxel—lung cancer	3.69e-05	0.000292	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—lung cancer	3.68e-05	0.000292	CcSEcCtD
Buprenorphine—Dizziness—Paclitaxel—lung cancer	3.64e-05	0.000289	CcSEcCtD
Buprenorphine—Nausea—Cisplatin—lung cancer	3.64e-05	0.000289	CcSEcCtD
Buprenorphine—Cough—Methotrexate—lung cancer	3.6e-05	0.000285	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—lung cancer	3.59e-05	0.000285	CcSEcCtD
Buprenorphine—Convulsion—Methotrexate—lung cancer	3.57e-05	0.000283	CcSEcCtD
Buprenorphine—Vomiting—Etoposide—lung cancer	3.57e-05	0.000283	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—lung cancer	3.57e-05	0.000283	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—lung cancer	3.57e-05	0.000283	CcSEcCtD
Buprenorphine—Rash—Etoposide—lung cancer	3.54e-05	0.000281	CcSEcCtD
Buprenorphine—Dermatitis—Etoposide—lung cancer	3.54e-05	0.00028	CcSEcCtD
Buprenorphine—Headache—Etoposide—lung cancer	3.52e-05	0.000279	CcSEcCtD
Buprenorphine—Flatulence—Doxorubicin—lung cancer	3.52e-05	0.000279	CcSEcCtD
Buprenorphine—Chest pain—Methotrexate—lung cancer	3.51e-05	0.000278	CcSEcCtD
Buprenorphine—Arthralgia—Methotrexate—lung cancer	3.51e-05	0.000278	CcSEcCtD
Buprenorphine—Myalgia—Methotrexate—lung cancer	3.51e-05	0.000278	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—lung cancer	3.5e-05	0.000278	CcSEcCtD
Buprenorphine—Vomiting—Paclitaxel—lung cancer	3.5e-05	0.000277	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—lung cancer	3.5e-05	0.000277	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	3.49e-05	0.000276	CcSEcCtD
Buprenorphine—Rash—Paclitaxel—lung cancer	3.47e-05	0.000275	CcSEcCtD
Buprenorphine—Dermatitis—Paclitaxel—lung cancer	3.47e-05	0.000275	CcSEcCtD
Buprenorphine—Discomfort—Methotrexate—lung cancer	3.47e-05	0.000275	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—lung cancer	3.47e-05	0.000275	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—lung cancer	3.45e-05	0.000274	CcSEcCtD
Buprenorphine—Headache—Paclitaxel—lung cancer	3.45e-05	0.000273	CcSEcCtD
Buprenorphine—Hypersensitivity—Docetaxel—lung cancer	3.44e-05	0.000273	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—lung cancer	3.43e-05	0.000272	CcSEcCtD
Buprenorphine—Confusional state—Methotrexate—lung cancer	3.39e-05	0.000269	CcSEcCtD
Buprenorphine—Anaphylactic shock—Methotrexate—lung cancer	3.37e-05	0.000267	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—lung cancer	3.37e-05	0.000267	CcSEcCtD
Buprenorphine—Asthenia—Docetaxel—lung cancer	3.35e-05	0.000265	CcSEcCtD
Buprenorphine—Infection—Methotrexate—lung cancer	3.34e-05	0.000265	CcSEcCtD
Buprenorphine—Nausea—Etoposide—lung cancer	3.34e-05	0.000264	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—lung cancer	3.31e-05	0.000262	CcSEcCtD
Buprenorphine—Pruritus—Docetaxel—lung cancer	3.3e-05	0.000262	CcSEcCtD
Buprenorphine—Nervous system disorder—Methotrexate—lung cancer	3.3e-05	0.000261	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—lung cancer	3.28e-05	0.00026	CcSEcCtD
Buprenorphine—Nausea—Paclitaxel—lung cancer	3.27e-05	0.000259	CcSEcCtD
Buprenorphine—Skin disorder—Methotrexate—lung cancer	3.27e-05	0.000259	CcSEcCtD
Buprenorphine—Hyperhidrosis—Methotrexate—lung cancer	3.25e-05	0.000258	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—lung cancer	3.22e-05	0.000255	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—lung cancer	3.21e-05	0.000254	CcSEcCtD
Buprenorphine—Anorexia—Methotrexate—lung cancer	3.21e-05	0.000254	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—lung cancer	3.2e-05	0.000254	CcSEcCtD
Buprenorphine—Diarrhoea—Docetaxel—lung cancer	3.2e-05	0.000253	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—lung cancer	3.16e-05	0.00025	CcSEcCtD
Buprenorphine—Hypotension—Methotrexate—lung cancer	3.15e-05	0.000249	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—lung cancer	3.14e-05	0.000249	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—lung cancer	3.12e-05	0.000247	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—lung cancer	3.09e-05	0.000245	CcSEcCtD
Buprenorphine—Dizziness—Docetaxel—lung cancer	3.09e-05	0.000245	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—lung cancer	3.08e-05	0.000244	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Methotrexate—lung cancer	3.07e-05	0.000243	CcSEcCtD
Buprenorphine—Insomnia—Methotrexate—lung cancer	3.04e-05	0.000241	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—lung cancer	3.04e-05	0.000241	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—lung cancer	3.04e-05	0.000241	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—lung cancer	3.04e-05	0.000241	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—lung cancer	3.03e-05	0.00024	CcSEcCtD
Buprenorphine—Paraesthesia—Methotrexate—lung cancer	3.02e-05	0.000239	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	3.02e-05	0.000239	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—lung cancer	3e-05	0.000238	CcSEcCtD
Buprenorphine—Dyspnoea—Methotrexate—lung cancer	3e-05	0.000238	CcSEcCtD
Buprenorphine—Somnolence—Methotrexate—lung cancer	2.99e-05	0.000237	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—lung cancer	2.97e-05	0.000236	CcSEcCtD
Buprenorphine—Vomiting—Docetaxel—lung cancer	2.97e-05	0.000235	CcSEcCtD
Buprenorphine—Dyspepsia—Methotrexate—lung cancer	2.96e-05	0.000235	CcSEcCtD
Buprenorphine—Rash—Docetaxel—lung cancer	2.94e-05	0.000233	CcSEcCtD
Buprenorphine—Dermatitis—Docetaxel—lung cancer	2.94e-05	0.000233	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—lung cancer	2.94e-05	0.000233	CcSEcCtD
Buprenorphine—Decreased appetite—Methotrexate—lung cancer	2.93e-05	0.000232	CcSEcCtD
Buprenorphine—Headache—Docetaxel—lung cancer	2.93e-05	0.000232	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—lung cancer	2.91e-05	0.000231	CcSEcCtD
Buprenorphine—Oedema—Doxorubicin—lung cancer	2.91e-05	0.000231	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Methotrexate—lung cancer	2.91e-05	0.00023	CcSEcCtD
Buprenorphine—Fatigue—Methotrexate—lung cancer	2.9e-05	0.00023	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—lung cancer	2.9e-05	0.000229	CcSEcCtD
Buprenorphine—Pain—Methotrexate—lung cancer	2.88e-05	0.000228	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—lung cancer	2.87e-05	0.000227	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—lung cancer	2.86e-05	0.000226	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—lung cancer	2.84e-05	0.000225	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—lung cancer	2.83e-05	0.000224	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—lung cancer	2.82e-05	0.000223	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—lung cancer	2.78e-05	0.00022	CcSEcCtD
Buprenorphine—Nausea—Docetaxel—lung cancer	2.77e-05	0.00022	CcSEcCtD
Buprenorphine—Feeling abnormal—Methotrexate—lung cancer	2.77e-05	0.00022	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Methotrexate—lung cancer	2.75e-05	0.000218	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—lung cancer	2.72e-05	0.000216	CcSEcCtD
Buprenorphine—Urticaria—Methotrexate—lung cancer	2.67e-05	0.000212	CcSEcCtD
Buprenorphine—Abdominal pain—Methotrexate—lung cancer	2.66e-05	0.000211	CcSEcCtD
Buprenorphine—Body temperature increased—Methotrexate—lung cancer	2.66e-05	0.000211	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.66e-05	0.00021	CcSEcCtD
Buprenorphine—Insomnia—Doxorubicin—lung cancer	2.64e-05	0.000209	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—lung cancer	2.62e-05	0.000207	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—lung cancer	2.6e-05	0.000206	CcSEcCtD
Buprenorphine—Somnolence—Doxorubicin—lung cancer	2.59e-05	0.000205	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—lung cancer	2.57e-05	0.000203	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—lung cancer	2.53e-05	0.000201	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—lung cancer	2.52e-05	0.000199	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—lung cancer	2.51e-05	0.000199	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—lung cancer	2.49e-05	0.000197	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—lung cancer	2.49e-05	0.000197	CcSEcCtD
Buprenorphine—Hypersensitivity—Methotrexate—lung cancer	2.48e-05	0.000196	CcSEcCtD
Buprenorphine—Asthenia—Methotrexate—lung cancer	2.42e-05	0.000191	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—lung cancer	2.4e-05	0.00019	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—lung cancer	2.38e-05	0.000189	CcSEcCtD
Buprenorphine—Pruritus—Methotrexate—lung cancer	2.38e-05	0.000189	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—lung cancer	2.32e-05	0.000183	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—lung cancer	2.3e-05	0.000182	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—lung cancer	2.3e-05	0.000182	CcSEcCtD
Buprenorphine—Diarrhoea—Methotrexate—lung cancer	2.3e-05	0.000182	CcSEcCtD
Buprenorphine—Dizziness—Methotrexate—lung cancer	2.23e-05	0.000176	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—lung cancer	2.15e-05	0.00017	CcSEcCtD
Buprenorphine—Vomiting—Methotrexate—lung cancer	2.14e-05	0.00017	CcSEcCtD
Buprenorphine—Rash—Methotrexate—lung cancer	2.12e-05	0.000168	CcSEcCtD
Buprenorphine—Dermatitis—Methotrexate—lung cancer	2.12e-05	0.000168	CcSEcCtD
Buprenorphine—Headache—Methotrexate—lung cancer	2.11e-05	0.000167	CcSEcCtD
Buprenorphine—Asthenia—Doxorubicin—lung cancer	2.09e-05	0.000166	CcSEcCtD
Buprenorphine—Pruritus—Doxorubicin—lung cancer	2.06e-05	0.000163	CcSEcCtD
Buprenorphine—Nausea—Methotrexate—lung cancer	2e-05	0.000158	CcSEcCtD
Buprenorphine—Diarrhoea—Doxorubicin—lung cancer	1.99e-05	0.000158	CcSEcCtD
Buprenorphine—Dizziness—Doxorubicin—lung cancer	1.93e-05	0.000153	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—lung cancer	1.85e-05	0.000147	CcSEcCtD
Buprenorphine—Rash—Doxorubicin—lung cancer	1.84e-05	0.000146	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—lung cancer	1.84e-05	0.000145	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—lung cancer	1.83e-05	0.000145	CcSEcCtD
Buprenorphine—Nausea—Doxorubicin—lung cancer	1.73e-05	0.000137	CcSEcCtD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.63e-06	3.1e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—APOA1—lung cancer	2.63e-06	3.1e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALDOA—lung cancer	2.62e-06	3.1e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—lung cancer	2.62e-06	3.09e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—JUN—lung cancer	2.61e-06	3.08e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTEN—lung cancer	2.61e-06	3.08e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—lung cancer	2.6e-06	3.07e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CAT—lung cancer	2.58e-06	3.04e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—STAT3—lung cancer	2.58e-06	3.04e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ABCB1—lung cancer	2.57e-06	3.03e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NRAS—lung cancer	2.57e-06	3.03e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP2E1—lung cancer	2.57e-06	3.03e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CB—lung cancer	2.57e-06	3.03e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CA—lung cancer	2.55e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NCOA3—lung cancer	2.55e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CB—lung cancer	2.54e-06	3e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—lung cancer	2.54e-06	3e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—lung cancer	2.54e-06	3e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MDM2—lung cancer	2.54e-06	3e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NQO1—lung cancer	2.54e-06	3e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1A—lung cancer	2.53e-06	2.99e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RAF1—lung cancer	2.53e-06	2.99e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTEN—lung cancer	2.53e-06	2.98e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TYMS—lung cancer	2.53e-06	2.98e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—lung cancer	2.52e-06	2.97e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.51e-06	2.97e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB2—lung cancer	2.5e-06	2.96e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTP1—lung cancer	2.5e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTM1—lung cancer	2.5e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—EP300—lung cancer	2.49e-06	2.94e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.49e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ADCY1—lung cancer	2.48e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCG2—lung cancer	2.48e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTP1—lung cancer	2.48e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MTOR—lung cancer	2.47e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CB—lung cancer	2.47e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TYMS—lung cancer	2.47e-06	2.91e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—lung cancer	2.47e-06	2.91e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.46e-06	2.91e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK3—lung cancer	2.46e-06	2.91e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTM1—lung cancer	2.44e-06	2.88e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CAT—lung cancer	2.43e-06	2.87e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ENO2—lung cancer	2.43e-06	2.87e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HPGDS—lung cancer	2.43e-06	2.87e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPP2R1B—lung cancer	2.42e-06	2.85e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CAT—lung cancer	2.41e-06	2.84e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EP300—lung cancer	2.41e-06	2.84e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CG—lung cancer	2.4e-06	2.83e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.4e-06	2.83e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—lung cancer	2.4e-06	2.83e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL8—lung cancer	2.38e-06	2.8e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP1A1—lung cancer	2.37e-06	2.79e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ABCB1—lung cancer	2.37e-06	2.79e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—lung cancer	2.36e-06	2.78e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTT1—lung cancer	2.36e-06	2.78e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ERCC2—lung cancer	2.35e-06	2.77e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ABCB1—lung cancer	2.35e-06	2.77e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SRC—lung cancer	2.34e-06	2.77e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—lung cancer	2.34e-06	2.76e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—lung cancer	2.33e-06	2.75e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GCLC—lung cancer	2.33e-06	2.75e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2A6—lung cancer	2.33e-06	2.75e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CB—lung cancer	2.33e-06	2.75e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TYMS—lung cancer	2.32e-06	2.74e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP1A1—lung cancer	2.31e-06	2.73e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—lung cancer	2.31e-06	2.72e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TYMS—lung cancer	2.3e-06	2.72e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTM1—lung cancer	2.3e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—lung cancer	2.29e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ERCC2—lung cancer	2.29e-06	2.7e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—STK11—lung cancer	2.29e-06	2.7e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—POMC—lung cancer	2.28e-06	2.69e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—lung cancer	2.28e-06	2.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTM1—lung cancer	2.28e-06	2.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—APOA1—lung cancer	2.28e-06	2.68e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP3—lung cancer	2.27e-06	2.68e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL2—lung cancer	2.27e-06	2.68e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT3—lung cancer	2.26e-06	2.67e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—lung cancer	2.26e-06	2.66e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NRAS—lung cancer	2.25e-06	2.66e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CREBBP—lung cancer	2.22e-06	2.62e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTEN—lung cancer	2.22e-06	2.61e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—lung cancer	2.21e-06	2.61e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—lung cancer	2.21e-06	2.61e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ENO1—lung cancer	2.21e-06	2.61e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—JUN—lung cancer	2.21e-06	2.61e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTEN—lung cancer	2.2e-06	2.59e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.18e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP1A1—lung cancer	2.18e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ERCC2—lung cancer	2.16e-06	2.55e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK3—lung cancer	2.16e-06	2.55e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP1A1—lung cancer	2.16e-06	2.55e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—lung cancer	2.15e-06	2.53e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.15e-06	2.53e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ERCC2—lung cancer	2.14e-06	2.53e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1A—lung cancer	2.14e-06	2.53e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTEN—lung cancer	2.14e-06	2.52e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTP1—lung cancer	2.12e-06	2.5e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—EP300—lung cancer	2.11e-06	2.49e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CD—lung cancer	2.11e-06	2.49e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—lung cancer	2.1e-06	2.48e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—EP300—lung cancer	2.1e-06	2.47e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—lung cancer	2.08e-06	2.46e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ALB—lung cancer	2.08e-06	2.46e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CG—lung cancer	2.08e-06	2.45e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CAT—lung cancer	2.06e-06	2.43e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—lung cancer	2.05e-06	2.42e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.05e-06	2.42e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EP300—lung cancer	2.04e-06	2.4e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—lung cancer	2.03e-06	2.4e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOA1—lung cancer	2.03e-06	2.4e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTEN—lung cancer	2.01e-06	2.38e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ABCB1—lung cancer	2e-06	2.36e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOA1—lung cancer	1.98e-06	2.34e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2E1—lung cancer	1.98e-06	2.34e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SRC—lung cancer	1.98e-06	2.34e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—POMC—lung cancer	1.98e-06	2.33e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TYMS—lung cancer	1.97e-06	2.32e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—lung cancer	1.97e-06	2.32e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NQO1—lung cancer	1.96e-06	2.31e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTM1—lung cancer	1.95e-06	2.3e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.94e-06	2.29e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—lung cancer	1.94e-06	2.29e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—lung cancer	1.93e-06	2.28e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CREBBP—lung cancer	1.93e-06	2.27e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—EP300—lung cancer	1.92e-06	2.27e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT3—lung cancer	1.91e-06	2.25e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NRAS—lung cancer	1.91e-06	2.25e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—lung cancer	1.9e-06	2.25e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—lung cancer	1.88e-06	2.22e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOA1—lung cancer	1.87e-06	2.2e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CG—lung cancer	1.85e-06	2.19e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOA1—lung cancer	1.85e-06	2.18e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP1A1—lung cancer	1.84e-06	2.18e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—lung cancer	1.84e-06	2.17e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CB—lung cancer	1.84e-06	2.17e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ERCC2—lung cancer	1.83e-06	2.16e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CD—lung cancer	1.83e-06	2.15e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK3—lung cancer	1.83e-06	2.15e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—lung cancer	1.82e-06	2.15e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CG—lung cancer	1.81e-06	2.14e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ALB—lung cancer	1.8e-06	2.13e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—lung cancer	1.8e-06	2.12e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—lung cancer	1.78e-06	2.1e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—lung cancer	1.78e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.77e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—STK11—lung cancer	1.77e-06	2.08e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—POMC—lung cancer	1.77e-06	2.08e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—lung cancer	1.74e-06	2.05e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—lung cancer	1.72e-06	2.03e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—POMC—lung cancer	1.72e-06	2.03e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CREBBP—lung cancer	1.72e-06	2.03e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CG—lung cancer	1.71e-06	2.01e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CG—lung cancer	1.69e-06	1.99e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CREBBP—lung cancer	1.68e-06	1.98e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—lung cancer	1.66e-06	1.96e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—lung cancer	1.65e-06	1.95e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—lung cancer	1.64e-06	1.93e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTP1—lung cancer	1.63e-06	1.93e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CD—lung cancer	1.63e-06	1.92e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—POMC—lung cancer	1.62e-06	1.92e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—POMC—lung cancer	1.61e-06	1.9e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ALB—lung cancer	1.61e-06	1.9e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CB—lung cancer	1.59e-06	1.88e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CD—lung cancer	1.59e-06	1.88e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CAT—lung cancer	1.59e-06	1.88e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTEN—lung cancer	1.59e-06	1.87e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOA1—lung cancer	1.58e-06	1.87e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CREBBP—lung cancer	1.58e-06	1.87e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—lung cancer	1.58e-06	1.86e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—lung cancer	1.58e-06	1.86e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ALB—lung cancer	1.57e-06	1.85e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CREBBP—lung cancer	1.57e-06	1.85e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—lung cancer	1.56e-06	1.84e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—lung cancer	1.55e-06	1.83e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCB1—lung cancer	1.55e-06	1.82e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMS—lung cancer	1.52e-06	1.79e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.52e-06	1.79e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—EP300—lung cancer	1.51e-06	1.79e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—lung cancer	1.51e-06	1.78e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—lung cancer	1.51e-06	1.78e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTM1—lung cancer	1.5e-06	1.77e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CD—lung cancer	1.5e-06	1.77e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CD—lung cancer	1.49e-06	1.75e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ALB—lung cancer	1.48e-06	1.75e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ALB—lung cancer	1.47e-06	1.73e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—lung cancer	1.46e-06	1.72e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—lung cancer	1.46e-06	1.72e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CG—lung cancer	1.44e-06	1.7e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP1A1—lung cancer	1.42e-06	1.68e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CB—lung cancer	1.42e-06	1.68e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—lung cancer	1.42e-06	1.68e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ERCC2—lung cancer	1.41e-06	1.67e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—lung cancer	1.41e-06	1.66e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—lung cancer	1.39e-06	1.64e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CB—lung cancer	1.39e-06	1.64e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTEN—lung cancer	1.38e-06	1.62e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—POMC—lung cancer	1.38e-06	1.62e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—lung cancer	1.37e-06	1.62e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CREBBP—lung cancer	1.34e-06	1.58e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—lung cancer	1.33e-06	1.57e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—EP300—lung cancer	1.31e-06	1.55e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CB—lung cancer	1.31e-06	1.54e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CB—lung cancer	1.3e-06	1.53e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—lung cancer	1.29e-06	1.53e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—lung cancer	1.28e-06	1.51e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—lung cancer	1.28e-06	1.51e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CD—lung cancer	1.27e-06	1.5e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—lung cancer	1.27e-06	1.49e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALB—lung cancer	1.25e-06	1.48e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—lung cancer	1.23e-06	1.45e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTEN—lung cancer	1.23e-06	1.45e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOA1—lung cancer	1.22e-06	1.44e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTEN—lung cancer	1.2e-06	1.41e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—EP300—lung cancer	1.17e-06	1.38e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—lung cancer	1.16e-06	1.37e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—EP300—lung cancer	1.14e-06	1.35e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTEN—lung cancer	1.13e-06	1.33e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—lung cancer	1.12e-06	1.32e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTEN—lung cancer	1.12e-06	1.32e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CG—lung cancer	1.12e-06	1.32e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CB—lung cancer	1.11e-06	1.31e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—lung cancer	1.1e-06	1.29e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—EP300—lung cancer	1.08e-06	1.27e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—EP300—lung cancer	1.07e-06	1.26e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—POMC—lung cancer	1.06e-06	1.25e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CREBBP—lung cancer	1.03e-06	1.22e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CD—lung cancer	9.8e-07	1.16e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—lung cancer	9.7e-07	1.14e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALB—lung cancer	9.68e-07	1.14e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTEN—lung cancer	9.57e-07	1.13e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—lung cancer	9.15e-07	1.08e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—EP300—lung cancer	9.12e-07	1.08e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—lung cancer	8.66e-07	1.02e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CB—lung cancer	8.54e-07	1.01e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—lung cancer	8.47e-07	9.99e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—lung cancer	8.45e-07	9.97e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—lung cancer	7.97e-07	9.4e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—lung cancer	7.93e-07	9.35e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—lung cancer	7.9e-07	9.32e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTEN—lung cancer	7.38e-07	8.71e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—lung cancer	7.08e-07	8.35e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—EP300—lung cancer	7.04e-07	8.31e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—lung cancer	6.91e-07	8.15e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—lung cancer	6.75e-07	7.96e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—lung cancer	6.51e-07	7.68e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—lung cancer	6.45e-07	7.61e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—lung cancer	5.51e-07	6.5e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—lung cancer	5.21e-07	6.14e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—lung cancer	4.26e-07	5.02e-06	CbGpPWpGaD
